AASLD-EASL HBV Endpoints 2022

Published on 05/08/2022

3-4 June, 2022
Washington, US

ENYO Pharma was attending AASLD-EASL HBV Endpoints 2022 to share news on therapeutic endpoints, trial designs and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. It was a great opportunity to meet academic, regulatory, pharmaceutical communities and patients in liver disease area.

https://easl.eu/event/aasld-easl-endpoints-2022/

Read next in 'Events'

• J.P. Morgan week and WuXi Global Forum 2025 in San Francisco
• J.P. Morgan week et WuXi Global Forum 2025 à San Francisco
• 4th Rare & Genetic Kidney Disease Drug Development Summit
• 4th Rare & Genetic Kidney Disease Drug Development Summit
• MOSAIC - Global NASH Trialist Forum 2024